Deals In Depth: August 2018
Executive Summary
In a partnership worth up to $5 billion, Affimed and Genentech will discovery innate immune cell immunotherapies for solid and hematological tumors. Emergent BioSolutions did two acquisitions, one in infectious disease (PaxVax) and the other in opioid overdose (Adapt Pharma). Biopharma financing reached nearly $4 billion, while device fundraising was just over $1 billion.